NAFLD - Nonalcoholic Fatty Liver Disease Clinical Trial
Official title:
Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial
A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase 2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).
Children ages 8-17 years weighing between 70 -149 kilograms will be enrolled and treated with losartan (100 mg orally once per day) or matching placebo for 24 weeks. The hypothesis is that losartan will improve serum alanine aminotransferase (ALT) in children with pediatric NAFLD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03583437 -
Hepatic and Cardiac Metabolic Flexibility in Obese With NAFLD.
|
N/A | |
| Recruiting |
NCT04371042 -
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
|
||
| Recruiting |
NCT02581085 -
Tocotrienol Against the Progression of End Stage Liver Disease
|
Phase 2 | |
| Recruiting |
NCT06115876 -
Kuwait Adult Diabetes Epidemiological Multidisciplinary (KADEM) Program
|
||
| Recruiting |
NCT05218538 -
Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
|
||
| Completed |
NCT04480710 -
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
|
Phase 2 | |
| Withdrawn |
NCT04109742 -
Curcumin for Pediatric Nonalcoholic Fatty Liver Disease
|
Phase 2 | |
| Recruiting |
NCT03646292 -
Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver
|
Phase 4 | |
| Completed |
NCT03678727 -
Effects of Exercise on VLDL-TG Metabolism
|